Loading…
Loading grant details…
| Funder | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE |
|---|---|
| Recipient Organization | Boston University Medical Campus |
| Country | United States |
| Start Date | Aug 15, 2024 |
| End Date | Jul 31, 2029 |
| Duration | 1,811 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 10865638 |
PROJECT SUMMARY/ABSTRACT Septic shock is a common, often fatal, dysregulated host response to infection that results in acute circulatory failure. Almost all patients with septic shock either have anemia (i.e., low blood counts) on presentation or develop anemia during hospitalization and anemia in septic shock is strongly associated with morbidity and
mortality. Almost 60% of patients with septic shock receive autologous red blood cell transfusions to treat anemia once hemoglobin levels drop below 7.0 g/dL (threshold-based transfusion strategy). However, there is conflicting guidance and evidence for whether all patients with septic shock and hemoglobin levels
Boston University Medical Campus
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant